Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANEB Anebulo Pharmaceuticals	$2.85 +6.7%	$1.69	$0.80 ▼ $3.42	$117.09M	-0.89	1.13 million shs	141,348 shs
ANVS Annovis Bio	$2.51 -8.1%	$2.64	$1.11 ▼ $10.54	$48.91M	1.51	324,064 shs	349,630 shs
ELEV Elevation Oncology	$0.37	$0.36	$0.22 ▼ $3.09	$21.62M	1.48	1.18 million shs	N/A
ONCY Oncolytics Biotech	$0.99 -2.9%	$0.80	$0.33 ▼ $1.53	$96.43M	1.09	1.31 million shs	537,614 shs

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for August 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANEB Anebulo Pharmaceuticals	0.00%	-10.66%	+67.16%	+147.83%	+18.75%
ANVS Annovis Bio	0.00%	-13.89%	+5.24%	+55.42%	-73.10%
ELEV Elevation Oncology	0.00%	0.00%	-5.19%	+4.29%	-86.12%
ONCY Oncolytics Biotech	0.00%	-5.71%	+9.88%	+80.00%	-4.81%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ANEB Anebulo Pharmaceuticals	1.5893 of 5 stars	3.3	3.0	0.6	1.7	0.0
ANVS Annovis Bio	2.1576 of 5 stars	3.5	1.0	2.6	1.7	0.6
ELEV Elevation Oncology	2.6728 of 5 stars	3.0	5.0	0.0	1.7	0.6
ONCY Oncolytics Biotech	2.4521 of 5 stars	3.4	5.0	2.9	0.0	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ANEB Anebulo Pharmaceuticals	2.50	Moderate Buy	$5.50	92.98% Upside
ANVS Annovis Bio	3.00	Buy	$18.00	617.13% Upside
ELEV Elevation Oncology	2.00	Hold	$3.39	827.59% Upside
ONCY Oncolytics Biotech	2.75	Moderate Buy	$4.33	337.71% Upside

Current Analyst Ratings Breakdown

Latest ANVS, ELEV, ONCY, and ANEB Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/23/2025	ANEB Anebulo Pharmaceuticals	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
6/10/2025	ELEV Elevation Oncology	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform ➝ Market Perform
6/10/2025	ELEV Elevation Oncology	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Neutral
6/9/2025	ANVS Annovis Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$30.00 ➝ $12.00
6/9/2025	ELEV Elevation Oncology	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
6/9/2025	ELEV Elevation Oncology	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/21/2025	ONCY Oncolytics Biotech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00 ➝ $5.00
5/16/2025	ONCY Oncolytics Biotech	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold
5/15/2025	ANEB Anebulo Pharmaceuticals	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$6.00 ➝ $3.00
5/15/2025	ANVS Annovis Bio	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$26.00 ➝ $17.00

(Data available from 8/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ANEB Anebulo Pharmaceuticals	N/A	N/A	N/A	N/A	$0.15 per share	N/A
ANVS Annovis Bio	N/A	N/A	N/A	N/A	$0.67 per share	N/A
ELEV Elevation Oncology	N/A	N/A	N/A	N/A	$1.02 per share	N/A
ONCY Oncolytics Biotech	N/A	N/A	N/A	N/A	$0.05 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ANEB Anebulo Pharmaceuticals	-$8.20M	-$0.26	N/A	∞	N/A	N/A	-90.11%	-84.53%	9/23/2025 (Estimated)
ANVS Annovis Bio	-$24.59M	-$2.16	N/A	N/A	N/A	N/A	-300.56%	-193.50%	8/13/2025 (Estimated)
ELEV Elevation Oncology	-$44.49M	-$0.82	N/A	N/A	N/A	N/A	-74.68%	-48.14%	8/5/2025 (Estimated)
ONCY Oncolytics Biotech	-$23.14M	-$0.29	N/A	N/A	N/A	N/A	-313.77%	-130.19%	8/7/2025 (Estimated)

Latest ANVS, ELEV, ONCY, and ANEB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q2 2025	ANVS Annovis Bio	-$0.36	N/A	N/A	N/A	N/A	N/A
8/7/2025	Q2 2025	ONCY Oncolytics Biotech	-$0.10	N/A	N/A	N/A	N/A	N/A
8/5/2025	Q2 2025	ELEV Elevation Oncology	-$0.26	N/A	N/A	N/A	N/A	N/A
5/15/2025	Q1 2025	ELEV Elevation Oncology	-$0.20	-$0.24	-$0.04	-$0.24	N/A	N/A
5/14/2025	Q1 2025	ONCY Oncolytics Biotech	-$0.09	-$0.06	+$0.03	-$0.06	N/A	N/A
5/13/2025	Q3 2025	ANEB Anebulo Pharmaceuticals	-$0.05	-$0.04	+$0.01	-$0.04	N/A	N/A
5/13/2025	Q1 2025	ANVS Annovis Bio	-$0.47	-$0.32	+$0.15	-$0.32	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ANEB Anebulo Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ANVS Annovis Bio	N/A	N/A	N/A	N/A	N/A
ELEV Elevation Oncology	N/A	N/A	N/A	N/A	N/A
ONCY Oncolytics Biotech	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ANEB Anebulo Pharmaceuticals	N/A	25.29	25.29
ANVS Annovis Bio	N/A	10.68	10.68
ELEV Elevation Oncology	0.67	19.40	19.40
ONCY Oncolytics Biotech	N/A	3.20	3.20

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ANEB Anebulo Pharmaceuticals	28.40%
ANVS Annovis Bio	15.83%
ELEV Elevation Oncology	83.70%
ONCY Oncolytics Biotech	6.82%

Insider Ownership

Company	Insider Ownership
ANEB Anebulo Pharmaceuticals	80.60%
ANVS Annovis Bio	20.80%
ELEV Elevation Oncology	8.10%
ONCY Oncolytics Biotech	0.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ANEB Anebulo Pharmaceuticals	4	41.08 million	7.97 million	Not Optionable
ANVS Annovis Bio	3	19.49 million	15.43 million	Optionable
ELEV Elevation Oncology	40	59.22 million	54.43 million	Optionable
ONCY Oncolytics Biotech	30	97.41 million	97.31 million	Not Optionable

ANVS, ELEV, ONCY, and ANEB Headlines

Recent News About These Companies

Analysts Set Oncolytics Biotech Inc. (NASDAQ:ONCY) Target Price at $4.33

August 2 at 2:06 AM | americanbankingnews.com

Oncolytics Biotech (ONCY) Projected to Post Earnings on Thursday

July 31 at 3:38 AM | marketbeat.com

Oncolytics Biotech Inc. (NASDAQ:ONCY) Given Average Rating of "Moderate Buy" by Brokerages

July 30, 2025 | marketbeat.com

Oncolytics Biotech® to Engage FDA for Potential Registration-Enabled Study in First-Line Pancreatic Cancer with Goal to Launch Trial Activities by Year-End

July 29, 2025 | prnewswire.com

Oncolytics Biotech (NASDAQ:ONCY) Stock Price Up 3.8% - Time to Buy?

July 29, 2025 | marketbeat.com

Key Opinion Leader Event Highlights Pelareorep’s Compelling Pancreatic and Gastrointestinal Data And Future Potential

July 25, 2025 | cantechletter.comC

Cancer Surge Meets Funding Crunch as Breakthrough Biotechs Line Up Milestones in 2025

July 24, 2025 | baystreet.ca

Oncolytics Biotech Inc.: Oncolytics Biotech Regains Compliance with Nasdaq Trading Rules

July 24, 2025 | finanznachrichten.de

High‑Growth Oncology Market Projected For US$900bn in Revenue Despite Policy Headwinds

July 24, 2025 | newswire.ca

Oncolytics Biotech Highlights Pelareorep’s Potential in Pancreatic Cancer at KOL Event

July 23, 2025 | tipranks.com

Key Opinion Leader Event Highlights Pelareorep's Compelling Pancreatic and Gastrointestinal Data And Future Potential

July 23, 2025 | prnewswire.com

Oncolytics Biotech Regains Nasdaq Compliance as of July 22, 2025

July 22, 2025 | tipranks.com

Oncolytics Biotech® Regains Compliance with Nasdaq Trading Rules

July 22, 2025 | prnewswire.com

Oncolytics Biotech® Presents Aggregated Translational Data Providing Evidence of Pelareorep's Effectiveness Across Multiple Tumor Types

July 16, 2025 | prnewswire.com

Oncolytics Biotech Inc. (ONCY) - Yahoo Finance Canada

July 11, 2025 | ca.finance.yahoo.com

USA News Group: Cancer Innovation Accelerates as Funding Cuts Loom and Biotechs Step Up

July 10, 2025 | finanznachrichten.de

Oncolytics Biotech to Host Webinar on Pelareorep’s Potential in Cancer Treatment

July 10, 2025 | tipranks.com

Oncolytics Biotech® to Host Key Opinion Leader Discussion Focusing on Pancreatic and Gastrointestinal Cancers

July 10, 2025 | prnewswire.com

Oncolytics Biotech Highlights Promising Pelareorep Data in Cancer Treatment

July 10, 2025 | theglobeandmail.com

Global Oncology Breakthroughs Being Fueled by Advancements in Clinical Trials and New Therapies - The Globe and Mail

July 9, 2025 | theglobeandmail.com

Oncolytics Biotech® Highlights Transformative Pelareorep Survival Data in Multiple Tumors and Commitment to Registration-Enabling Studies

July 8, 2025 | prnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

3 Defense Leaders Set to Gain From Rising Military Spend
By Chris Markoch | July 5, 2025
View 3 Defense Leaders Set to Gain From Rising Military Spend
3 Short Squeeze Candidates With Big Catalysts on the Horizon
By Dan Schmidt | July 25, 2025
View 3 Short Squeeze Candidates With Big Catalysts on the Horizon
How a Government Loan Changes the Game for Plug Power
By Jeffrey Neal Johnson | July 4, 2025
View How a Government Loan Changes the Game for Plug Power
Why Centene Stock Dropped 40% — And Whether It's a Buy Now
By Leo Miller | July 8, 2025
View Why Centene Stock Dropped 40% — And Whether It's a Buy Now
3 Overbought Stocks Ripe for a Pullback
By Ryan Hasson | July 7, 2025
View 3 Overbought Stocks Ripe for a Pullback

ANVS, ELEV, ONCY, and ANEB Company Descriptions

Anebulo Pharmaceuticals NASDAQ:ANEB

$2.85 +0.18 (+6.74%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$2.86 +0.00 (+0.18%)

As of 08/1/2025 07:52 PM Eastern

Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI. Anebulo Pharmaceuticals, Inc. was incorporated in 2020 and is based in Lakeway, Texas.

Annovis Bio NYSE:ANVS

$2.51 -0.22 (-8.06%)

Closing price 08/1/2025 03:59 PM Eastern

Extended Trading

$2.54 +0.03 (+1.24%)

As of 08/1/2025 06:30 PM Eastern

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405, which is in Phase 2 and Phase 3 efficacy studies, an intravenous drug for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials, an orally administered drug to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Malvern, Pennsylvania.

Elevation Oncology NASDAQ:ELEV

$0.36 0.00 (0.00%)

As of 07/23/2025

Elevation Oncology, Inc., an oncology company, focuses on the discovery and development of cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. The company's lead candidate is EO-3021, an antibody-drug conjugate designed to target Claudin 18.2, a clinically validated molecular target. Its EO-3021 selectively delivers a cytotoxic payload directly to cancer cells expressing Claudin 18.2. Elevation Oncology, Inc. has a license agreement with CSPC Megalith Biopharmaceutical Co., Ltd. to develop and commercialize EO-3021. The company was formerly known as 14ner Oncology, Inc. and changed its name to Elevation Oncology, Inc. in February 2020. The company was incorporated in 2019 and is based in Boston, Massachusetts.

Oncolytics Biotech NASDAQ:ONCY

$0.99 -0.03 (-2.94%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$1.00 +0.01 (+1.52%)

As of 08/1/2025 07:56 PM Eastern

Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep, as well as with Roche Holding AG. The company was incorporated in 1998 and is headquartered in Calgary, Canada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time